Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04865887 · ClinicalTrials.gov registry record · Phase 2
Pembrolizumab and Lenvatinib in Advanced Cervical Cancer
A Phase 2 study of Cervical Cancer and Metastatic Cervical Cancer, sponsored by Georgetown University.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 35
- Enrollment target
- 4
- Study locations
NCT04865887 is a Phase 2 study of Cervical Cancer and Metastatic Cervical Cancer that is actively recruiting participants, run by Georgetown University. The registered enrollment target is 35 participants, below the 570-participant average among 144 other Cervical Cancer trials with a reported enrollment target (94% lower). The trial reports 4 study locations across 3 states.
The verdict
NCT04865887, a Phase 2 study of Cervical Cancer and Metastatic Cervical Cancer, is actively recruiting participants, sponsored by Georgetown University.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 35 participants
- Enrollment target
- 4
- Study locations
Study Summary
This is a phase II trial of combination therapy of pembrolizumab and lenvatinib in patients with locally advanced or metastatic cervical cancer that had failed first line of therapy. The hypothesis is the combination of lenvatinib and pembrolizumab will overcome vascular endothelial growth factor (VEGF)-mediated immunosuppression to enhance the response of patients with locally advanced or metastatic cervical cancer.
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG Lenvatinib
Study Locations (4)
District of Columbia
- MedStar Georgetown University Hospital - Washington D.C.
- Medstar Washington Hospital Center - Washington D.C.
Georgia
- Georgia Cancer Center at Augusta University - Augusta
New Jersey
- John Theurer Cancer Center at Hackensack UMC - Hackensack
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2022-10-07 |
| Est. Completion | 2026-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04865887
The ClinicalTrials.gov registry entry for NCT04865887 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 570-participant average among 144 other Cervical Cancer trials with a reported enrollment target (94% lower). The listed sponsor is Georgetown University, which has 227 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Cervical Cancer appearing as the primary indexed condition, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT04865887 reports 4 study locations spanning 3 distinct geographic areas - top geographies include District of Columbia, Georgia, New Jersey.
Frequently Asked Questions
What is clinical trial NCT04865887 about?
NCT04865887 is a clinical study titled "Pembrolizumab and Lenvatinib in Advanced Cervical Cancer". This is a phase II trial of combination therapy of pembrolizumab and lenvatinib in patients with locally advanced or metastatic cervical cancer that had failed first line of therapy. The hypothesis is the combination of lenvatinib and pembrolizumab will overcome vascular endothelial growth factor (V...
What is the current status of trial NCT04865887?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 35 participants. The study started on 2022-10-07. Estimated completion is 2026-07.
What conditions does trial NCT04865887 study?
This clinical trial studies the following conditions: Cervical Cancer, Metastatic Cervical Cancer.
What interventions are being tested in trial NCT04865887?
The interventions under investigation include: Pembrolizumab (DRUG), Lenvatinib (DRUG).
Who is sponsoring clinical trial NCT04865887?
This trial is sponsored by Georgetown University, which has 227 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04865887 being conducted?
This trial has 4 study locations across District of Columbia, Georgia, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cervical Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
PRGN-2009 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer
RECRUITING · Phase 2
-
Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors
RECRUITING · Phase 2
-
E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers
RECRUITING · Phase 2
-
A Study of Sacituzumab Govitecan (IMMU-132) in Patients With Recurrent or Persistent Cervical Cancer
RECRUITING · Phase 2
-
Study of Pembrolizumab and Lenvatinib in Metastatic and Recurrent Cervix Cancer (LenPem Cervix)
RECRUITING · Phase 2
-
PROton Therapy for Post Surgical Treatment of GYNecologic Cancer
RECRUITING · Phase 2
Explore more on PlainTrial
Cervical Cancer
All registered trials for this condition
Metastatic Cervical Cancer
All registered trials for this condition
District of Columbia
All trials with a study site in District of Columbia
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.